At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 114 enrolled
Drug / intervention
VRC-HIVADV014-00-VP +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine or the Multiclade HIV-1 Adenoviral Vector Vaccine Alone in Healthy Adult Volunteers Not Infected With HIV
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jul 26, 2005·Updated Nov 1, 2021
In Brief
A Phase 1 clinical trial evaluating VRC-HIVADV014-00-VP and VRC-HIVDNA016-00-VP for HIV Infections. Completed, enrolled 114 participants across 3 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine the safety of and immune response to an investigational HIV vaccine, VRC-HIVADV014-00-VP, with or without a second investigational HIV vaccine, VRC-HIVDNA016-00-VP, in HIV uninfected adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesKenya, Rwanda
Collaborators--
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2005
Enrollment StartNov 2005
Study CompletionApr 2007
TodayJul 2026
First PostedJul 26, 2005
Enrollment StartNov 1, 2005
Study CompletionApr 1, 2007
TodayJul 2, 2026
Posted 20.9 years ago
Interventions
VRC-HIVADV014-00-VPbiological
VRC-HIVDNA016-00-VPbiological